Sign in to fuzzto save your conversations, follow your research and come back anytime.
Dr Reddys Laboratories
SectorHealthcare
In the news
PB Fintech Crashes 48% in 6 Sessions, Hits IPO Price
Dr Reddy's shares up 3rd straight day, target raised 39%
Nifty Crashes Below 22,500: Iran-US Tensions Drive Market Rout
Dr Reddy's shares rise 1% on Nomura 'Buy' rating, Rs1,740 target
Dr. Reddy's Qdenga Gamble: First-Mover Edge in India's Dengue Vaccine Race
Dr Reddy's shares climb 3% on exclusive dengue vaccine deal with Takeda
JM Financial sees 28% upside in Dr Reddy's, Aurobindo Pharma
Market Experts' Stock Picks: Dr Reddy's, BEL, L&T, HDFC Bank
Dr Reddy's launches cancer drug biosimilar NIVORZ in India
Dr Reddy's Mexico API facility gets 2 FDA observations
Dr. Reddy's Biologics Facility: Three Years of USFDA Scrutiny
Corporate Developments: Dr Reddy's, Adani Green, JSW Energy, KIMS, Nestlé, NLC India, LIC
Dr Reddy's Q4 FY26: Navigating R&D Setbacks and US Market Headwinds
Dr. Reddy's Generic Semaglutide: A Canadian First-Mover Advantage
Dr. Reddy's Hit with ₹8.38 Cr GST Penalties
Company insights, generated from the most recent coverage.
6-month return -11.5% and 1-year -5% means the stock is still in recovery mode from a longer correction, so it amplifies every macro wobble.
Stock has just crossed its 200-DMA, and that level is acting as the first profit-booking zone for short-term traders.
No adverse BSE filings in Sep 2026 — today's fall is macro plus positioning, not a fresh company-specific trigger. Note: the COO exit flagged on Sep 29 remains an unresolved management watchpoint.